Tilray Brands (TLRY) Q2 2026 earnings review
Record Revenue Masking a Beverage Breakdown
Tilray delivered record Q2 net revenue of $218M (+3% YoY) and cut its Net Loss by nearly half to $43.5M. However, the headline growth hides a significant deterioration in the Beverage segment, where revenue plunged 21% and margins compressed by 900 basis points. The quarter was salvaged by a massive 36% surge in International Cannabis and record volume in the low-margin Distribution business. While the company achieved a net cash position of $27.4M, the heavy lifting is being done by legacy pharma distribution and cannabis, while the 'diversified alcohol' thesis faced a sharp reversal this quarter.
🐂 Bull Case
The European strategy is paying off. International cannabis revenue jumped 36% YoY to $20.2M. With regulatory tailwinds in Germany and potential U.S. rescheduling, Tilray's global footprint is generating tangible growth.
Net loss narrowed significantly (-49% YoY), and the company swung to a Net Cash position of $27.4M (from net debt in Q1). Operating cash burn improved to $8.5M from $40.7M a year ago, signaling better capital discipline.
🐻 Bear Case
The diversification thesis took a hit. Beverage revenue fell 21% YoY to $50.1M (down from $63.1M), and gross margins collapsed from 40% to 31%. Management cites SKU rationalization, but the scale of the drop suggests demand issues or integration struggles.
Consolidated gross margin compressed to 26% (vs. 29% YoY). The growth is coming from the low-margin Distribution segment (13% margin), which now accounts for 39% of total revenue, while the high-margin Beverage segment shrinks.
⚖️ Verdict: ⚪
Neutral. The improved balance sheet and international cannabis traction are positives, but the sudden double-digit decline in the Beverage segment—previously touted as a key growth engine—is a major concern that creates uncertainty around the diversification strategy.
Key Themes
Beverage Segment Reversal
Beverage revenue dropped to $50.1M this quarter from $63.1M a year ago (-21%), and gross profit fell from $25.2M to $15.7M (-38%). Gross margin contracted sharply to 31% from 40%. While 'SKU rationalization' was mentioned in prior quarters, the acceleration of this decline raises flags about the organic health of the craft beer portfolio.
International Cannabis Surge
Accelerating. International cannabis revenue grew 36% YoY to $20.2M. This high-margin segment is benefiting from regulatory changes in Germany and improved flow of medical cannabis products. It now represents 30% of total cannabis revenue, up from 23% last year.
Mix-Shift Drag on Margins
The Distribution business (Tilray Pharma) had its highest revenue quarter ever at $85.3M (+26% YoY). However, this segment carries a structural 13% gross margin. As this low-margin segment outpaces the rest of the business, it weighs on consolidated gross margin, which fell to 26% from 29%.
Cannabis Margin Expansion
Despite Canadian market challenges, Cannabis segment gross margin improved to 39% from 35% YoY. This validates the strategy of focusing on cost reductions and prioritizing higher-margin international sales over low-margin Canadian wholesale volume.
Cash Burn Persists
While improved, the company is still burning cash from operations (-$8.5M). Free Cash Flow was -$18.1M. The shift to a 'net cash' position was aided by managing debt and marketable securities, but organic cash generation remains elusive.
Other KPIs
Stable. Down slightly from $9.0M in the prior year. Despite revenue growth, EBITDA did not expand, reflecting the margin compression in the Beverage segment.
Accelerating improvement. Net loss was nearly cut in half from $(85.3)M in the prior year period. EPS improved to $(0.41) from $(0.99).
Strong. Cash and marketable securities rose to $292M. The company highlighted a Net Cash position of $27.4M, a significant turnaround from a Net Debt position of $3.8M in Q1.
Guidance
Stable. Management reaffirmed guidance. With $18.5M generated in H1 ($10.2M Q1 + $8.4M Q2), the company needs to generate ~$43-53M in H2 to hit targets. This implies a significant acceleration (back-end weighting) is required in Q3/Q4.
Key Questions
Beverage Segment Deterioration
Beverage revenue fell 21% YoY and margins compressed 900bps to 31%. Is this entirely due to SKU rationalization, or are we seeing organic demand erosion in the craft beer portfolio? When do you expect this segment to return to growth?
H2 Earnings Ramp
To meet the reaffirmed FY26 EBITDA guidance of $62-72M, you need to generate over $43M in the second half—more than double the H1 performance. What specific drivers give you confidence in this steep sequential acceleration?
Gross Margin Sustainability
Cannabis margins hit a robust 39%, but consolidated margins fell to 26% due to the Distribution mix. With Distribution growing fastest (+26%), do you see consolidated gross margin remaining structurally lower in the mid-20s?